Comparison of the Hypoglucemic Effects of Erythropoietin and U-74389G on Glucose Levels

Aim: This study calculated the hypoglucemic capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the hypoglucemic influence, after the respective drug usage in an induced hypoxia reoxygenation animal experiment. Materials and Methods: The 2 main experimental endpoints at which the glucose (Gl) levels were evaluated was the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration. Results: The first preliminary study of Epo presented a non significant hypoglucemic effect by 0.84%+1.12% (p-value=0.4430). The second preliminary study of U-74389G presented a significant hypoglucemic effect by 3.94%+1.06% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 4.660603-fold more hypoglucemic potency than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G enhance the acute hypoglucemic properties presenting 4.660603-fold more intentive hypoglucemia than Epo (p-value=0.0000).